Veeva Systems (VEEV) Q1 FY27 earnings call: guidance and Q&A

How does Falcon target specific roles, and how does it interplay with Vault and standard agents?

Peter explains Falcon as the "next chapter" for Veeva, focusing on "agentic labor" to fully replace parts of jobs, distinct from Vault AI which assists users within applications. Falcon is disruptive because it automates tasks previously done by humans, leveraging Veeva's deep industry knowledge and application access.

“Falcon specifically is at the agent layer and that's agentic labor. So fully replacing parts -- jobs that people used to do.”

asked by Joseph Vruwink · answered by Peter Gassner

What areas will pharma lean into first for AI, and how will the transition from traditional SaaS to AI applications occur?

Peter clarifies that pharma isn't transitioning *from* SaaS to AI, but adopting a MAAP (Models, Agents, Applications) architecture. They seek more efficient applications with embedded AI and aim to become "agentic biopharma" where agents handle high-volume, standardized tasks (e.g., 100 million clinical trial documents, safety case triage), freeing humans for higher-value work. Veeva's structural advantage lies in its industry depth, consulting, and applications.

“What they're really leaning into is this new technical architecture, we call it the MAAP architecture of Models, Agents and Applications.”

asked by Brian Peterson · answered by Peter Gassner

How will Falcon be priced, and which labor roles are being targeted for automation?

Peter states that initial target roles are high-volume, repetitive tasks often outsourced, such as processing clinical trial documentation (intake, quality check, categorization, filing) and safety cases (triage, categorization, collection), as well as regulatory health authority correspondences. Pricing is expected to be by document for documentation processing and by case for safety.

“In terms of how we're going to charge for those, you can imagine most likely that Falcon will be charged by the document, most likely. We haven't fully decided that. You can imagine that safety will be most likely charged by the case.”

asked by David Windley · answered by Peter Gassner

Could Falcon's displacement of roles cannibalize existing Veeva revenue?

Peter asserts that Falcon will be "definitely all accretive" because Veeva does not currently address the market for the labor it aims to automate. He emphasizes that agents require a system of record, which Falcon does not cannibalize.

“Definitely all accretive because this is not a market we address today. We don't play in that market today. This is not type of labor or work that we supply.”

asked by Andrew DeGasperi · answered by Peter Gassner

Update on Top 20 CRM migration decisions and when cross-sell opportunities will be pursued.

Paul reports strong progress in Vault CRM, with significant global wins (Teva, Merck KGaA) and a win rate over 80%. Among the original "Top 20" list, Veeva has 10 wins, Salesforce has 6, and 4 decisions remain, with Veeva expecting to win the majority. Over 150 customers are live on Vault CRM, with over 40 migrations completed.

“So we won Merck KGaA and Teva, but we don't count them in that top 20. The remaining 4, there's 10 wins for Veeva so far, 6 for Salesforce. So there's 4 decisions left. We expect to win the majority of those 4 remaining decisions.”

asked by David Hynes · answered by Paul Shawah

What is the strategic rationale for Ostro, how will it gain visibility, and what is its contribution to commercial revenue guidance?

Paul explains Ostro as a brand engagement platform for biopharma, enabling compliant, instantaneous Q&A for HCPs and patients. Biopharma companies will drive engagement. It integrates with digital channels like OpenEvidence and unlocks "Commercial Evidence" by providing unfiltered insights into HCP/patient needs. Brian adds that Ostro, acquired late in Q1, is expected to contribute $10 million to revenue in the remaining three quarters of FY27, accounting for two-thirds of the $15 million increase in commercial subs guidance.

“Ostro is super exciting... It's a brand engagement platform for biopharma companies to help HCPs and patients ask questions and get answers instantaneously and do that in a compliant way.”

asked by Ryan MacDonald · answered by Paul Shawah

Is Veeva taking share from CROs with AI, and could commercial AI agents take share from platforms like Doximity?

Peter clarifies that agentic labor targets high-volume, repetitive work often outsourced to specialized labor providers, not typically CROs. This could benefit CROs by enabling pharma to run more trials. In commercial, AI agents will augment field teams (e.g., drafting emails, sending reminders) rather than replace them. Platforms like Ostro enable new capabilities (e.g., 24/7 HCP/patient engagement) that were previously impossible, rather than directly taking share from Doximity.

“The best places to do are high-volume repetitive work that actually gets outsourced. So that type of work actually it's not so much the CROs, it's other specialized labor providers that do that.”

asked by David Larsen · answered by Peter Gassner